Écrit par GlobalData | 29 Novembre 2012

LONDON, UK (GlobalData), 28 November 2012  - Humira (adalimumab) has a strong reputation as a top anti-Tumor Necrosis Factor (TNF) and Rheumatoid Arthritis (RA) therapy, but a new report by healthcare experts GlobalData states that the future emergence of the anticipated cheaper biosimilars, and new novel oral RA products, may well see the blockbuster begin to loose its lustre.

In this new...

Écrit par GlobalData | 26 Novembre 2012

LONDON, UK (GlobalData), 20 November 2012 - Biotech companies are exploring alternative options to supplement their in-house research and development (R&D), abandoning the traditional blockbuster drug model to instead pursue deals and buy their way to success, says healthcare intelligence providers GlobalData in a new report, which explores the new strategies that biotech pharmaceutical...

Écrit par EMBO | 20 Novembre 2012

HEIDELBERG, 20 November 2012 – Scientists have engineered bacteria that are capable of sacrificing themselves for the good of the bacterial population. These altruistically inclined bacteria, which are described online in the journal Molecular Systems Biology, can be used to demonstrate the conditions where programmed cell death becomes a distinct advantage for the survival of the bacterial...

Écrit par GBI | 15 Novembre 2012

NEW YORK (GBI Research), 15 November 2012 - Intravenous (IV) drips are fast evolving, as patients take their treatment in to the home, states a new report by healthcare experts GBI Research.




The new report* states that diseases such as cancer, Acquired Immune Deficiency Syndrome (AIDS) and Gastrointestinal (GI) disorders are becoming more common, due in part to a globally ageing...